AngioDynamics and UCLH launch study of ‘long term effects’ of NanoKnife System

AngioDynamics (ANGO) announced the launch of an international multi-center prospective registry study to assess the long term effects of treating men with unifocal intermediate-risk prostate cancer with the NanoKnife System in partnership with the University College London Hospital UCLH. Approximately 40% of all diagnosed prostate cancer cases are classified as intermediate risk.1 In the first year after surgery, 36% of men report urinary leakage, and 95% are affected by erectile dysfunction 70% described as moderate/severe The NanoKnife System delivers an innovative alternative to conventional radical surgery or radiotherapy, each of which often results in significant dysfunction in urinary continence and erectile potency. With its non-thermal approach, the NanoKnife system is engineered to preserve vital structures inside and outside the prostate, offering patients effective treatment of tumors, low complication rates, and minimal impact on quality of life.3